Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy

被引:123
作者
Martinez, LR [1 ]
Casadevall, A [1 ]
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
关键词
D O I
10.1128/IAI.73.10.6350-6362.2005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
One of the most troublesome medical problems today is infection of prosthetic devices with organisms that form polysaccharide biofilms. This combined with increasing antimicrobial drug resistance is making many infectious diseases incurable. Cryptococcus neoformans is a human-pathogenic fungus that has a polysaccharide capsule and can form biofilms in prosthetic medical devices. We developed a system to study cryptococcal biofilm formation in vitro and studied the effect of antibody to the C. neoformans capsular polysaccharide on this process. C neoformans biofilm formation was dependent on the presence of a polysaccharide capsule and correlated with the ability of capsular polysaccharide to bind the polystyrene solid support. Protective antibodies prevented biofilm formation whereas nonprotective antibodies were not effective. The mechanism of antibody action involved interference with capsular polysaccharide release from the fungal cell. In contrast, lactoferrin, an effector molecule of innate immune mechanisms, was unable to prevent fungal biofilm formation despite its efficacy against bacterial biofilms. Our results suggest a new role of adaptive humoral immunity whereby some antibodies can inhibit biofilm formation by encapsulated organisms. Vaccines that elicit antibody responses to capsular antigens and/or passive transfer of antibodies to microbial polysaccharides may be useful in preventing biofilm formation.
引用
收藏
页码:6350 / 6362
页数:13
相关论文
共 41 条
[1]   STRUCTURAL POLYMORPHISM OF BACTERIAL ADHESION PILI [J].
BULLITT, E ;
MAKOWSKI, L .
NATURE, 1995, 373 (6510) :164-167
[2]   Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies [J].
Casadevall, A ;
Cleare, W ;
Feldmesser, M ;
Glatman-Freedman, A ;
Goldman, DL ;
Kozel, TR ;
Lendvai, N ;
Mukherjee, J ;
Pirofski, LA ;
Rivera, J ;
Rosas, AL ;
Scharff, MD ;
Valadon, P ;
Westin, K ;
Zhong, ZJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1437-1446
[3]   Antibody-mediated regulation of cellular immunity and the inflammatory response [J].
Casadevall, A ;
Pirofski, LA .
TRENDS IN IMMUNOLOGY, 2003, 24 (09) :474-478
[4]   MONOCLONAL-ANTIBODY BASED ELISAS FOR CRYPTOCOCCAL POLYSACCHARIDE [J].
CASADEVALL, A ;
MUKHERJEE, J ;
SCHARFF, MD .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 154 (01) :27-35
[5]   THE MOUSE ANTIBODY-RESPONSE TO INFECTION WITH CRYPTOCOCCUS-NEOFORMANS - VH AND VL USAGE IN POLYSACCHARIDE BINDING-ANTIBODIES [J].
CASADEVALL, A ;
SCHARFF, MD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (01) :151-160
[6]   Biofilm formation by the fungal pathogen Candida albicans:: Development, architecture, and drug resistance [J].
Chandra, J ;
Kuhn, DM ;
Mukherjee, PK ;
Hoyer, LL ;
McCormick, T ;
Ghannoum, MA .
JOURNAL OF BACTERIOLOGY, 2001, 183 (18) :5385-5394
[7]   Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier [J].
Charlier, C ;
Chrétien, F ;
Baudrimont, M ;
Mordelet, E ;
Lortholary, O ;
Dromer, F .
AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (02) :421-432
[8]   CRYPTOCOCCUS-NEOFORMANS SEROTYPE-A GLUCURONOXYLOMANNAN-PROTEIN CONJUGATE VACCINES - SYNTHESIS, CHARACTERIZATION, AND IMMUNOGENICITY [J].
DEVI, SJN ;
SCHNEERSON, R ;
EGAN, W ;
ULRICH, TJ ;
BRYLA, D ;
ROBBINS, JB ;
BENNETT, JE .
INFECTION AND IMMUNITY, 1991, 59 (10) :3700-3707
[9]   Biofilms: Microbial life on surfaces [J].
Donlan, RM .
EMERGING INFECTIOUS DISEASES, 2002, 8 (09) :881-890
[10]   PROTECTION OF MICE AGAINST EXPERIMENTAL CRYPTOCOCCOSIS BY ANTI-CRYPTOCOCCUS-NEOFORMANS MONOCLONAL-ANTIBODY [J].
DROMER, F ;
CHARREIRE, J ;
CONTREPOIS, A ;
CARBON, C ;
YENI, P .
INFECTION AND IMMUNITY, 1987, 55 (03) :749-752